SEC Tracker
Get the app

Lycia Therapeutics LYCA

Lycia Therapeutics reports stock option grant

Sofia Touami, insider filing for LYCA

Form
4
Filed
Importance
Routine
  1. Stock option granted on Aug 11, 2026
  2. 68,755 shares underlying the option
  3. Option price $3.7
  4. Vesting over four years starting Sep 6, 2026

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Lycia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float not reported.

  1. Adaptimmune Therapeutics ADAP
  2. Adverum Biotechnologies ADVM
  3. AgomAb Therapeutics AGMB
  4. Alvotech ALVO
  5. Argenx ARGX